Press Releases

Keyword Search

News Category Financial

Year None20212020201920182017201620152014

Date	Title
05/05/21	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe
04/22/21	MediciNova Receives Gene Therapy Milestone Payments
04/19/21	MediciNova to Participate in the B. Riley Neuroscience Conference
04/15/21	MediciNova to Participate in the UBS Global Healthcare Virtual Conference
03/09/21	MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
03/08/21	MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
03/03/21	MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
01/31/21	MediciNova Announces Closing of US$20 Million Private Placement Transaction
01/18/21	MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan
01/11/21	MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners